Prosecutors allege that sales representatives recruited medical providers under reimbursement-linked agreements while supposed rebates and discounts concealed payments that rewarded product use, divided government reimbursements, and generated approximately $268 million in challenged wound-care claims.
WASHINGTON, DC — Federal prosecutors accuse Michael McMillan of building a nationwide wound-product distribution arrangement in which sales representatives recruited medical providers, commercial agreements promised substantial reimbursement margins, and ordinary-sounding discounts allegedly concealed illegal kickbacks.
The indictment portrays contracts, invoices, commission reports, reimbursement notices, checks, wire transfers, and provider communications as interconnected parts of one alleged system, rather than treating any isolated rebate, representative payment, or customer discount as criminal on its own.
McMillan, a fifty-five-year-old Las Vegas resident, remains presumed innocent, and prosecutors must prove beyond a reasonable doubt that the challenged arrangements were knowingly designed to induce federally reimbursable purchases, influence medical decisions, and support materially false claims.
The government’s theory depends heavily upon economic substance, because the indictment alleges that labels associated with conventional commerce masked transactions whose practical operation divided government reimbursements among Protectus companies, participating providers, and recruited sales representatives.
Careful analysis also requires a narrower description of the alleged intermediaries, because the charging document identifies sales representatives who recruited providers and earned contingent commissions, but does not describe an unidentified network of shell-company pass-through accounts handling every provider payment.
The Alleged Structure Behind the Commercial Language
The federal grand jury alleges that McMillan owned and controlled six Nevada limited-liability companies collectively called Protectus, through which he supplied skin-substitute products and helped participating practices submit claims to Medicare, TRICARE, and CHAMPVA.
Those companies were Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC, each allegedly operating within the broader distribution enterprise prosecutors described.
According to the indictment, the challenged conduct continued from approximately May 2019 through at least February 2026, giving investigators nearly seven years of contracts, product records, communications, claims, invoices, reimbursement deposits, commissions, and corporate transfers to examine.
The government alleges McMillan and his companies recruited physicians, podiatrists, nurse practitioners, and other providers by offering skin substitutes without upfront payment, thereby allowing practices to avoid paying Protectus before knowing whether a government program would reimburse a claim.
If a claim was denied, Protectus allegedly charged the provider nothing for the product, while a successful reimbursement triggered an invoice commonly representing sixty percent to seventy percent of the government payment received by the medical practice.
The provider allegedly retained the remaining thirty percent to forty percent, which prosecutors characterize as a guaranteed kickback that could produce thousands of dollars whenever a federally funded program reimbursed an individual skin-substitute claim.
That contingent structure matters because the provider’s product obligation allegedly changed according to the payer’s decision, creating no purchase cost after denial but preserving a predetermined practice margin whenever Medicare, TRICARE, or CHAMPVA approved reimbursement.
Contracts Allegedly Encoded the Reimbursement Split
The indictment does not publish a complete master agreement or reproduce every provider contract, but it describes a consistent course of dealing documented through percentage invoices, a provider’s reference to a new contract, and communications requesting corrected profit allocations.
One overt act alleges that a provider employee emailed McMillan after receiving an invoice and explained that the new contract provided a forty-percent profit, although the attached document reflected only thirty-five percent for the participating medical practice.
Prosecutors say McMillan forwarded that message to a Protectus employee and requested a correction, an exchange they may use to argue that provider margins were negotiated contractual features rather than incidental differences between wholesale acquisition and program reimbursement.
The defense may answer that a contractual margin is not automatically unlawful, particularly when a supplier assumes collection uncertainty, provides administrative support, carries product exposure, or uses disclosed pricing terms within a complicated reimbursement marketplace.
That response would not end the inquiry, because prosecutors can argue that the agreement’s timing, denial protection, percentage calculation, marketing presentation, claim assistance, and relationship with product selection collectively reveal an inducement that ordinary contract wording cannot sanitize.
The legal contest will therefore turn on what the agreements actually accomplished, what McMillan intended, what providers understood, and whether the financial incentives were knowingly tied to purchases, recommendations, orders, or arrangements for federally reimbursable products.
Sales Representatives Formed the Alleged Intermediary Layer
Prosecutors allege that McMillan hired sales representatives to recruit medical providers, explain the reimbursement-sharing model, and direct prospective customers toward Protectus skin-substitute products within the Northern District of Texas and elsewhere across the country.
The representatives allegedly told providers how the profit-sharing arrangement operated and described the financial return practices could retain for each reimbursed product, placing them between Protectus and clinicians as recruitment intermediaries within the alleged scheme.
Their compensation was allegedly tied directly to reimbursements generated by the providers they had recruited, meaning a representative earned money only after a practice received government payment and remitted Protectus its contractual share.
Once Protectus collected sixty percent to seventy percent of a provider’s reimbursement, McMillan allegedly paid the responsible representative a percentage of that receipt, linking representative compensation to the same claim outcome that controlled the provider invoice.
The indictment estimates that Protectus paid approximately $27 million to sales representatives under this model, describing those commissions as illegal kickbacks intended to induce medical referrals from providers using the company’s products within participating medical practices.
Sales commissions remain common and lawful across many industries, including healthcare distribution, so the disputed question is not whether representatives received performance compensation, but whether McMillan knowingly used payments to induce protected orders, recommendations, referrals, or purchases.
Prosecutors may argue that representatives crossed from ordinary selling into prohibited inducement when they recruited clinical decision-makers with guaranteed government-funded profit margins and received compensation calibrated to reimbursements produced through those recruited relationships.
Defense counsel may emphasize legitimate product education, customer service, account development, reimbursement support, and ordinary sales activity while challenging whether representatives actually controlled patient-level medical choices or understood any provider claim to contain false pricing information.
Reimbursements Allegedly Controlled Both Payment Layers
The indictment describes a synchronized arrangement in which government reimbursement triggered the provider’s obligation to Protectus and then triggered the representative’s commission, creating two downstream payments that allegedly depended on one successful federal claim.
This sequencing gives prosecutors a powerful narrative: money allegedly moved only after reimbursement, while denied claims produced no provider charge and therefore no corresponding Protectus revenue from which a representative commission would be calculated.
The government can align claim adjudication dates, insurer explanations, provider bank deposits, Protectus invoices, customer payments, commission reports, representative checks, and company transfers to determine whether the same pattern repeated across many participating practices.
A repeated chronology can support an inference of deliberate structure, although timing alone cannot establish illegality because ordinary contingent collections, sales commissions, financing terms, and customer-payment practices can also follow reimbursement within lawful businesses.
Prosecutors must therefore combine financial sequencing with evidence concerning recruitment language, contract provisions, pricing disclosures, billing assistance, participant knowledge, and McMillan’s alleged statements about the provider profits available through Protectus products during the charged period.
Rebates and Discounts as Alleged Cover
The Northern District of Texas enforcement announcement says McMillan disguised kickbacks as rebates or discounts while Protectus received approximately $174 million from challenged claims involving wound-care products supplied under the alleged arrangement across multiple participating practices.
Legitimate rebates and discounts exist throughout healthcare commerce, and federal law does not transform every price reduction into a kickback merely because a product is eventually reimbursed by a government program serving eligible beneficiaries.
The prosecution instead alleges that the labels concealed guaranteed reimbursement percentages retained by providers, no-cost treatment of denied claims, inflated acquisition-price disclosures, and compensation arrangements intended to induce medical providers to use Protectus products.
A March 2024 meeting described in the indictment could become especially important because McMillan allegedly told one provider that Protectus offered an average thirty-five-percent rebate and illustrated how collecting $180,000 monthly could leave that practice with $63,000.
Prosecutors also allege McMillan said during that meeting that he reviewed every Medicare claim to ensure Protectus products were billed at a price higher than what providers actually paid, an accusation McMillan can contest with complete evidence.
Calling a payment a rebate may support a lawful interpretation when properly structured, reported, and reconciled, but a commercial label cannot determine the outcome when prosecutors allege that the underlying purpose was to reward federally reimbursable product use.
The defense can challenge whether the quoted conversation was accurately recorded, whether surrounding explanations changed its meaning, whether the term rebate reflected customary pricing, and whether the government’s interpretation disregards legitimate risk assumed by Protectus.
Box 19 and the Alleged Acquisition-Price Misstatement
The indictment says medical providers were required to disclose their actual acquisition price, including discounts, rebates, refunds, and other adjustments, through information entered in Box 19 when submitting relevant Medicare claims for skin-substitute products.
Prosecutors allege McMillan and Protectus either submitted claims for providers or assisted their submissions while using inflated prices that did not reflect the practices’ actual obligations after reimbursement-contingent percentages and other adjustments were considered.
That claim-disclosure theory connects the alleged kickback structure to healthcare fraud, because the government contends the same arrangement that rewarded providers also produced inaccurate acquisition-price information that could increase or preserve federal reimbursement.
Investigators can test the allegation by comparing Box 19 entries with contracts, invoices, refunds, denial records, credits, payment spreadsheets, bank transfers, product shipments, and communications showing what each practice ultimately owed.
The defense can dispute whether prosecutors selected the correct pricing rule, properly treated contingent obligations, recognized legitimate collection and product risk, or proved McMillan knew a particular figure was false when a claim reached the payer.
An administrative mistake or reasonable regulatory disagreement does not automatically establish criminal fraud, while repeated directions to use figures known to exceed actual customer obligations could support the prosecution when combined with evidence of intentional concealment.
A Paid Claim, a Denied Claim, and a Percentage Invoice
One sequence from May 2024 alleges that a provider reported Medicare had reimbursed one skin-substitute claim for $9,024 while denying another, giving investigators a compact example of how the alleged commercial model operated after payer adjudication.
A Protectus employee allegedly explained that the paid claim would generate a forthcoming invoice, and that the company would help resolve the denied submission after receiving documentation showing the basis for Medicare’s rejection.
The employee later said Box 19 had been omitted and that the information required for resubmission appeared on a spreadsheet, potentially linking Protectus’s billing assistance to the price-disclosure field central to the government’s fraud theory.
Protectus then allegedly invoiced the provider $5,865.60, exactly sixty-five percent of the reported $9,024 reimbursement, while no comparable product charge was described for the claim that Medicare had denied at that time.
Prosecutors may present that sequence as a transactional miniature of the broader scheme, whereas the defense may argue it demonstrates transparent invoicing, genuine claim support, actual product delivery, and ordinary collection practices rather than concealed criminal conduct.
Invoices and Commission Reports as Evidence
Another indictment example describes an October 2022 invoice showing $53,625.60 collected, $16,087.68 kept by one provider, and $37,537.92 due to Protectus, figures that expressly divided reimbursement according to a seventy-percent company share.
The following month, an associate of one representative allegedly questioned missing commissions after receiving $44,035.92, and a Protectus employee responded that commission could be paid only when an office reported that insurance had reimbursed its claims.
A later commission report allegedly recorded a $120,611.73 payment to another representative, including $8,446.03 attributed to profits Protectus earned from the provider invoice that had divided the earlier $53,625.60 reimbursement.
These examples may help prosecutors show that invoices and commission reports were operational records reflecting one contingent system, rather than unrelated payments whose similar percentages and timing resulted merely from conventional commercial accounting.
The defense can demand complete reports, underlying contracts, corrections, expenses, product costs, customer histories, and surrounding correspondence, because isolated entries selected by prosecutors may omit context relevant to intent, legitimate services, or accurate allocation.
Refunds Allegedly Followed Reimbursement Reversals
The indictment also describes a provider asking Protectus to refund two product invoices after Medicare payments were being returned so claims could be rebilled under the provider’s company, with repayment promised after reimbursement arrived again.
Protectus allegedly processed the requested credit-card refund through its accounting system, an event prosecutors may cite as evidence that provider obligations rose and fell with reimbursement rather than with delivery or application of the skin-substitute products.
The defense may characterize the refund as responsible customer accommodation during a billing correction, particularly if products were supplied, claims were being resubmitted, and the underlying commercial agreement permitted credits during temporary payer reversals.
The episode illustrates why labels alone will not resolve the case, because one transaction can appear either as reimbursement-contingent kickback accounting or as reasonable management of a reversed payment, depending on context, intent, disclosure, and governing rules.
What Third-Party Intermediaries Means in This Case
The phrase third-party intermediaries should be used carefully because the indictment specifically identifies four anonymized sales representatives, alongside five anonymized medical providers, but does not allege that every payment passed through an independent shell company.
Those representatives allegedly connected Protectus with providers, communicated the profit arrangement, monitored customer reimbursements, and received commissions after recruited practices paid invoices, making them intermediaries in recruitment and compensation rather than necessarily custodians of provider kickbacks.
Provider margins allegedly remained with the practices from the government reimbursement itself, while Protectus collected its portion and later compensated representatives, creating related financial pathways without requiring one intermediary to physically transmit every challenged provider payment.
That distinction separates the McMillan allegations from other prosecutions in which authorities expressly describe pass-through accounts, nominee entities, cash withdrawals, or shell companies used to conceal the recipient, source, or movement of illegal payments.
Responsible reporting should therefore identify the alleged intermediary role precisely, explain the contractual and commission mechanisms prosecutors actually charged, and avoid adding unproven laundering structures merely because the case involves multiple companies and third parties.
Count Two Addresses Direct and Indirect Remuneration
Count Two alleges a conspiracy to defraud the United States and violate the federal Anti-Kickback Statute by offering or paying remuneration directly or indirectly, overtly or covertly, in cash or kind, including through checks and wire transfers.
The government alleges the conspiracy sought to enrich McMillan and others by submitting false claims, paying providers for product use, paying representatives for recruitment, concealing both payment streams, and diverting proceeds for personal benefit.
Because Count Two charges conspiracy, prosecutors must establish an unlawful agreement, McMillan’s knowing participation, the charged objective, and at least one overt act advancing that agreement rather than simply proving that a questionable payment occurred.
The indictment identifies overt acts involving invoices, contract language, commission questions, reimbursement notices, refunds, checks, meetings, and Box 19 guidance, giving both sides transaction-specific evidence through which to argue knowledge and intent at trial.
McMillan can challenge authorship, completeness, hearsay exceptions, business-record foundations, context, terminology, witness credibility, and the inference prosecutors ask jurors to draw from each document or communication during contested pretrial and trial proceedings in federal court.
The Financial Totals Require Careful Separation
Prosecutors allege government programs paid approximately $268 million on challenged skin-substitute claims, Protectus received approximately $174 million, and providers retained approximately $94 million under the arrangement characterized as illegal kickbacks throughout the charged period.
Those figures appear to describe divisions of the same reimbursement stream, meaning the $174 million and $94 million should not be added to the $268 million as though they represented independent government payments.
The approximately $27 million allegedly paid to sales representatives likewise came from the distribution side after Protectus received provider payments, so it should not be treated as another category of federal loss added atop the claim total.
Authorities separately reported seizing assets valued at approximately $35 million, while the indictment lists seven property transactions totaling roughly $6.28 million and seeks broad forfeiture remedies if prosecutors ultimately obtain qualifying convictions after future court proceedings.
Submitted claims, paid claims, provider margins, company receipts, representative commissions, personal income, seized property, restitution, and forfeiture describe different financial categories, and collapsing them into one number would materially distort the prosecution’s allegations.
The Remaining Seven Counts Concern Alleged Proceeds Transactions
Beyond the two conspiracy counts, the nine-count indictment charges seven monetary transactions exceeding $10,000 in property allegedly derived from the healthcare-fraud and kickback conspiracies, provisions frequently described as transactional money laundering under the applicable federal statute.
Those counts identify transactions associated with four residences, two luxury vehicles, and a private aircraft between December 2021 and September 2025, but they do not establish that every company payment or representative commission was itself laundering.
For each financial count, prosecutors must prove criminally derived property, McMillan’s legally sufficient knowledge, the required transaction and jurisdictional elements, and a value above the statutory threshold identified in federal law for each charged transaction.
McMillan can trace legitimate revenue, loans, financing, savings, unrelated deposits, business expenses, or commingled funds while challenging whether more than $10,000 in proven unlawful proceeds entered any selected property transaction identified in the indictment.
Seizure preserves property while litigation proceeds, whereas forfeiture permanently transfers qualifying interests only after authorized judicial findings, making neither the government’s possession nor its preliminary valuation equivalent to a conviction or final ownership determination.
Why Provider Independence Will Matter
Medical providers retain responsibility for patient assessment, product selection, wound documentation, and claim accuracy, allowing prosecutors to argue that guaranteed margins were designed to influence decisions made within trusted clinical and billing relationships.
McMillan’s defense may emphasize that clinicians independently chose products, real patients received actual skin substitutes, legitimate wounds received treatment, and sales representatives could not compel any provider to order a product or submit a claim.
The government need not prove that every medical decision was corrupted identically if it establishes the charged agreements and intended false claims, but claim-level differences can still weaken generalizations about knowledge, necessity, and causation.
Skin substitutes can provide legitimate clinical value, so the indictment should not be interpreted as condemning wound care generally, every Protectus product, every manufacturer, or every professional who encountered a product distributed through the companies.
What Prosecutors Must Ultimately Prove
For the healthcare-fraud conspiracy, prosecutors must establish a knowing agreement to execute a scheme involving materially false representations connected with healthcare benefit payments, not merely an aggressive business model, complicated pricing method, or regulatory error.
They must connect McMillan with the alleged falsity by showing he understood providers’ actual acquisition obligations, knowingly supported inflated disclosures, and intended the reimbursement-linked arrangement to generate claims that government programs would not lawfully pay.
For the kickback conspiracy, the government must prove the required corrupt intent behind payments to providers and representatives, while addressing arguments that the arrangements involved lawful discounts, legitimate services, or permissible compensation under applicable protections.
Evidence may include contracts, invoices, reimbursement data, claim forms, accounting records, representative agreements, commission reports, product shipments, witness testimony, recorded communications, and bank records assembled into a chronology covering the charged period for expert examination.
No individual invoice, contract percentage, sales commission, or rebate label necessarily proves the entire case, but prosecutors may ask jurors to consider how repeated features operated together across multiple providers and representatives during deliberations.
Potential Defense Arguments
Defense counsel can argue that Protectus assumed genuine payment risk, provided products before collection, performed legitimate billing support, used conventional sales representatives, disclosed business terms, and charged commercially reasonable amounts after successful reimbursement.
Attorneys may also contest the government’s interpretation of Box 19 requirements, the calculation of actual acquisition cost, the characterization of rebates, the reliability of cooperating witnesses, and the representativeness of selected communications spanning nearly seven years.
Contracts can support the defense when they document real obligations and legitimate services, although prosecutors can argue that written language cannot legalize remuneration knowingly intended to influence federally reimbursable orders or conceal inaccurate claim information.
Representative commissions can likewise reflect lawful work when based upon genuine services and compliant methodology, but compensation directly tied to federal reimbursements from recruited providers can invite heightened scrutiny when combined with alleged inducement language.
Those defenses do not automatically establish innocence, just as a grand jury indictment, large reimbursement figure, luxury-property allegation, or coordinated federal announcement does not establish guilt before a valid plea or trial verdict.
A Prominent Case Within the Regional Crackdown
An NBC 5 Dallas-Fort Worth report on the regional enforcement action highlighted allegations that providers retained 30% to 40% of reimbursements while Protectus allegedly collected the remaining share through the wound-product arrangement.
McMillan’s approximately $268 million case was announced as part of seven Northern District of Texas prosecutions involving thirteen defendants and more than $365 million in collective alleged billing, making it the district package’s largest individually disclosed matter.
The regional cases formed part of the 2026 National Health Care Fraud Takedown, which federal officials said charged 455 defendants across fifty-six districts in alleged schemes involving more than $6.5 billion in false claims.
Those collective totals increase public attention but cannot strengthen the case against McMillan, because allegations involving laboratories, hospice services, testing, medical equipment, or unrelated defendants must be established independently in separate judicial proceedings.
Compliance Lessons from the Alleged Contracting Model
Healthcare providers should independently review offers involving products supplied without upfront payment, complete denial protection, guaranteed reimbursement margins, percentage invoices, distributor-managed claim assistance, or financial projections based upon federally funded product use within any proposed arrangement.
Every acquisition-price disclosure should reconcile written contracts, invoices, credits, rebates, refunds, replacements, free goods, financing terms, denied-claim treatment, and side communications that change the customer’s ultimate economic obligation for a reimbursed item under the complete agreement.
Distributors should separate product education from inducements, establish pricing through compliant methods, monitor claim-support services, document genuine commercial risk, and prohibit representatives from promising clinicians predetermined income from government reimbursement within reimbursement-dependent healthcare markets.
Representative compensation deserves particular scrutiny when commissions rise automatically with federal payments generated by recruited prescribers, because legitimate services, fair valuation, objective performance measures, and applicable regulatory protections should be documented contemporaneously before implementation and renewal.
Compliance teams should trace representative transactions from product purchase through shipment, clinical use, claim preparation, payer adjudication, provider collection, supplier invoice, refund activity, company receipt, commission payment, owner distribution, and significant asset acquisition.
When credible concerns emerge, organizations should preserve records, suspend questionable arrangements, obtain qualified healthcare counsel and accounting advice, evaluate repayment or disclosure obligations, and avoid communications or transfers that could create separate concealment allegations.
Lawful Communications During Contract and Kickback Scrutiny
Amicus International Consulting’s crisis public-relations guidance emphasizes organized assessment, evidence preservation, accurate timelines, and disciplined communications, principles especially relevant when technical contract allegations become simplified into emotionally powerful claims about kickbacks, vulnerable patients, and luxury assets.
Its reputation-rebuilding resources similarly support sustained, credible public information, requiring affected organizations to distinguish commissions from adjudicated kickbacks, rebates from proven concealment, indictment from conviction, and seizure from final forfeiture during continuing public scrutiny.
Companies connected with a federal investigation should designate authorized spokespeople, coordinate factual statements with qualified counsel, preserve complete communications, correct demonstrable errors carefully, and avoid promising that authentic court records or legitimate reporting can disappear.
No ethical reputation strategy can obstruct investigators, influence witnesses, conceal assets, fabricate explanations, or substitute publicity for legal advocacy, but accurate terminology can help employees, patients, vendors, lenders, and families understand what remains unresolved.
What Happens Next
The case will proceed through discovery, pretrial motions, expert analysis, potential negotiations, asset litigation, and possibly trial, with extensive attention likely directed toward provider contracts, representative compensation, Box 19 disclosures, reimbursement data, and fund tracing.
Future filings may clarify whether named providers or representatives are cooperating, identify additional contracts, narrow the challenged claim universe, explain disputed pricing guidance, and reveal how prosecutors intend to prove McMillan’s knowledge across separate entities and relationships.
The defense may seek exclusion of evidence, challenge searches and seizures, contest expert methodology, attack statutory interpretations, separate lawful transactions from disputed claims, and demand individualized proof for every alleged financial count and forfeiture target.
Until McMillan enters a valid guilty plea or prosecutors establish every required element beyond a reasonable doubt, the healthcare-fraud, kickback, intermediary, contractual-concealment, proceeds-transaction, seizure, and forfeiture allegations remain unresolved under the continuing presumption of innocence.